185 studies on Ghrelin mimetic class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This case study suggests that ghrelin agonists like GHRP-2 may be a valuable therapeutic tool for a specific, challenging subset of anorexia nervosa patients: those who have overcome the psychological fear of food but…
The study demonstrates two distinct and effective pharmacological pathways to combat growth retardation caused by somatotropic axis deficiency. For users of growth hormone secretagogues, this provides evidence that **…
The GHRP-2 test emerges as a viable diagnostic tool for secondary adrenal failure, offering diagnostic power comparable to the established CRH stimulation test. For clinicians, this provides another option for assessi…
For athletes and regulatory bodies, this research provides a pathway to more effective and reliable anti-doping controls for hGH. The identification of `RAB31` and `FN1` as robust biomarkers could lead to new testing …
This research provides a cellular mechanism for ghrelin analogs like GHRP-2 exerting anti-inflammatory effects within the ovary. For biohackers or clinicians interested in female reproductive health, this suggests a p…
This research suggests that the GHRP-2 stimulation test could be a valuable addition to the diagnostic toolkit for TSH-producing pituitary adenomas, especially when traditional tests like the TRH test are inconclusive…
The identification of this novel GHRP-2 analogue highlights a concerning trend in illicit drug manufacturing: the deliberate modification of known prohibited substances to create 'designer' peptides that can evade det…
The findings suggest that the GHRP-2 test can replace the riskier insulin tolerance test for HPA axis assessment, but its application is highly specific. **Clinicians can consider using the GHRP2T in male patients wit…
This case highlights that serious endocrine disorders like **isolated ACTH deficiency** can manifest with vague, non-classical symptoms such as stomach discomfort, which are commonly attributed to more benign conditio…
This research provides a crucial tool for anti-doping agencies to identify the use of black market follistatin. The discovery that all tested genuine products contain His-tags is a game-changer for testing, as it prov…
The findings suggest that the `GHRP-2 test` is more than just a binary diagnostic tool for severe **AGHD**; it's a quantitative prognostic marker. For clinicians managing patients with **NFPA**, a very low peak GH res…
This automated system significantly enhances the capabilities of anti-doping programs. By enabling reliable, quantitative analysis from Dried Blood Spot samples, it makes collection less invasive and sample handling m…
This study provides strong evidence that dried blood spot testing is a viable, stable, and effective method for detecting GHRP-2 abuse. For anti-doping organizations, this validates a simpler, cheaper, and less invasi…
This case underscores the critical importance of comprehensive endocrine screening in patients presenting with CFS-like symptoms and fibromyalgia. Identifying and treating underlying hormone deficiencies, such as ACTH…
**Clinicians managing thalassemia-related growth failure** should note that standard stimulation testing may miss subnormal ultradian GH secretion, meaning affected patients could benefit from secretagogue-based proto…
**Continuous or prolonged central exposure to GH secretagogues drives desensitization**, not sensitization — a direct challenge to the assumption that chronic dosing linearly amplifies GH output. For peptide users and…
This comprehensive review underscores the broad therapeutic potential of GHS across multiple organ systems and conditions. The observed benefits, from cardioprotection and growth promotion to metabolic improvements an…
**Clinicians and researchers evaluating GH axis function** may have a meaningful alternative to the hypoglycemia-inducing ITT already in view: the **GHRH + GHRP-6 combination at saturating doses** is flagged as the mo…
**The central mechanism of GH secretagogues does not depend on intact noradrenergic circuitry**, which has direct implications for clinical and research contexts in which noradrenergic tone is altered — such as stress…
This research provides crucial analytical and preparative separation techniques essential for the development of new growth hormone secretagogue drugs. By enabling the purification of individual diastereomers, it allo…
**GHRPs — particularly hexarelin — should be understood as direct cardiac agents**, not merely GH secretagogues; clinicians and researchers evaluating these compounds for body composition or GH-axis support must accou…
The study successfully identified adenosine as a partial agonist of the GHS-R, meaning it can activate the receptor but not to its full potential. Activation of GHS-R by adenosine was significantly inhibited by select…
**Hexarelin and MK-0677 do not bind to the same receptor populations in peripheral tissues** — a distinction with direct implications for anyone selecting between peptidyl and non-peptidyl GHS compounds. For cardiovas…
**The octanoyl fatty-acid modification on ghrelin is non-negotiable for receptor engagement**, directly validating why unacylated ghrelin fragments lack GH-releasing potency. For clinicians and researchers, this confi…
**The identification of `GPR38` as a GHS-R family member with motilin as its ligand** reveals that GH secretagogue pharmacology is entangled with gut-motility signaling — a consideration for clinicians and researchers…
**The endocardial endothelium is a required intermediary for hexarelin's cardiac effects**, which reframes hexarelin as an endothelium-targeting agent rather than a direct myocardial inotrope. For clinicians and resea…
**Oral bioavailability combined with significant anabolic output** positions SM-130686 in the same practical niche as MK-677 but with a structurally novel scaffold — potentially relevant for researchers seeking altern…
**Peptidyl GHS compounds like hexarelin may carry direct anticancer activity in lung carcinoma independent of their GH-releasing function**, a mechanistic split with major implications for therapeutic development and …
This comprehensive review highlights ghrelin's multifaceted nature, demonstrating it is far more than just a GH secretagogue. Understanding ghrelin's broad actions opens new avenues for therapeutic development and dru…
**The cardioprotection afforded by ghrelin and hexarelin appears to be independent of growth hormone secretion**, meaning GH-axis side effects are unlikely to be required for — or necessarily coupled to — the cardiac …
**Des-acyl ghrelin is not metabolically inert** — it directly suppresses fat breakdown at nanomolar concentrations equal to acylated ghrelin, fundamentally revising how practitioners should interpret circulating ghrel…
**GHS compounds including GHRP-2, GHRP-6, and MK-677 target four converging GH-axis nodes simultaneously**, which explains their superior efficacy over single-mechanism secretagogues and provides a pharmacological rat…
**The type of GHSR agonist chosen determines not just direct receptor activation but also how the body's own ghrelin pulses are amplified or suppressed.** For clinicians and researchers, this means MK-677's pharmacolo…
This synthesis highlights the GH/IGF-I axis as a critical endocrine regulator in Alzheimer's disease, offering a novel perspective on its pathogenesis. Understanding this intricate relationship could pave the way for …
**Identifying a shared TM-III/TM-VI hotspot across peptide and nonpeptide GHSR agonists** means that medicinal chemistry efforts can converge on this core cleft rather than treating each chemotype as starting from scr…
**The ago-allosteric model for MK-677 and GHRP-6 is not supported in this assay system** — meaning assumptions about synergistic or supra-additive effects when combining ghrelin-pathway compounds with these secretagog…
The discovery of these novel, orally active growth hormone secretagogues represents a significant advancement in the field of endocrinology and drug development. Oral administration offers a more convenient and patien…
**NN703 demonstrates that oral GH secretagogue therapy is pharmacologically viable**, with a 30% bioavailability and 4.1-hour half-life that are compatible with once-daily dosing — a profile ipamorelin itself cannot a…
**The quantified SC50 of 214 nmol/L gives clinicians and researchers a concrete pharmacological benchmark** for designing ipamorelin dosing regimens — doses that push plasma concentrations well above this threshold sh…